Catalyst Biosciences, Inc. (NASDAQ:CBIO) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by $1.07, MarketWatch Earnings reports. Catalyst Biosciences had a negative net margin of 2,961.29% and a negative return on equity of 95.60%. The business had revenue of $0.11 million during the quarter.

Catalyst Biosciences (NASDAQ CBIO) traded up 4.03% on Friday, reaching $3.87. 76,125 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $4.42 and its 200-day moving average is $5.74. Catalyst Biosciences has a 12 month low of $3.64 and a 12 month high of $23.25. The firm’s market cap is $16.49 million.

An institutional investor recently bought a new position in Catalyst Biosciences stock. Bank of New York Mellon Corp acquired a new position in shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 22,891 shares of the biopharmaceutical company’s stock, valued at approximately $107,000. Bank of New York Mellon Corp owned about 0.54% of Catalyst Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 5.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/04/catalyst-biosciences-inc-cbio-releases-quarterly-earnings-results-misses-expectations-by-1-07-eps.html.

Several equities research analysts recently issued reports on the stock. Ladenburg Thalmann Financial Services assumed coverage on shares of Catalyst Biosciences in a research note on Tuesday, June 6th. They issued a “buy” rating and a $11.00 price objective for the company. Chardan Capital assumed coverage on shares of Catalyst Biosciences in a research note on Monday, June 12th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “strong-buy” rating and set a $6.75 price objective for the company in a research note on Tuesday, April 11th.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Earnings History for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.